Find answers to your most challenging questions with the help of IDNLearn.com's experts. Our community provides timely and precise responses to help you understand and solve any issue you face.
About 40% of metastatic melanoma patients treated with anti-PD-1 or anti-PD-L1 therapy develop some antitumor immune responses that delay cancer progression or even lead to complete remissions. Why do you think that some patients respond to checkpoint blockade therapy, while others do not?
Sagot :
Your engagement is important to us. Keep sharing your knowledge and experiences. Let's create a learning environment that is both enjoyable and beneficial. Thanks for visiting IDNLearn.com. We’re dedicated to providing clear answers, so visit us again for more helpful information.